Wajant Harald
Department of Molecular Internal Medicine, Medical Polyclinic, University of Wuerzburg, Roentgenring 11, 97070 Wuerzburg, Germany.
Cancer Treat Res. 2006;130:141-65. doi: 10.1007/0-387-26283-0_7.
The membrane-bound death ligands CD95L/FasL and TRAIL, which activate the corresponding death receptors CD95/Fas, TRAILR1 and TRAILR2, induce apoptosis in many tumour cells, but can also elicit an inflammatory response. This chapter focuses on the relevance of CD95L/FasL and TRAIL for the tumour surveillance function of natural killer cells and cytotoxic T-cells and discuss current concepts of utilizing these ligands in tumour therapy.
膜结合死亡配体CD95L/FasL和TRAIL可激活相应的死亡受体CD95/Fas、TRAILR1和TRAILR2,在许多肿瘤细胞中诱导凋亡,但也可引发炎症反应。本章重点关注CD95L/FasL和TRAIL与自然杀伤细胞和细胞毒性T细胞的肿瘤监视功能的相关性,并讨论在肿瘤治疗中利用这些配体的当前概念。